33 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
strategy of investing in innovative life sciences companies whose goals are to help improve outcomes for patients. We look forward to working … innovative, novel combination of RNA and oncolytic virus-based modalities designed to realize the potential of RNA medicines for cancer. Our lead IV
8-K
EX-99.1
ONCR
Oncorus, Inc.
23 Jun 22
Oncorus Appoints Douglas Fambrough to Board of Directors
7:21am
in financing innovative life science technology companies. While at Oxford, Dr. Fambrough led the investment in the first-generation RNA interference … ) Immunotherapy Platform, highlighted by our product candidates ONCR-021 and ONCR-788, involves a highly innovative, novel combination of RNA and oncolytic
8-K
EX-99.1
ONCR
Oncorus, Inc.
21 Jun 21
Oncorus Appoints Eric Rubin, M.D. to its Board of Directors
4:03pm
innovative technologies into both of its platforms, which may enable the oncolytic virus modality to finally achieve its cancer-fighting and life-saving … Immunotherapy Platform involves a highly innovative, novel combination of RNA- and oncolytic virus-based modalities to realize the potential of RNA
8-K
EX-99.1
ONCR
Oncorus, Inc.
27 May 21
Regulation FD Disclosure
7:15am
. Our proprietary Synthetic vRNA Immunotherapy Platform involves a highly innovative, novel combination of RNA- and OV-based modalities and, in doing so … to the therapy, which we believe could potentially limit systemic toxicities. Our pioneering Synthetic vRNA Immunotherapy Platform involves a highly innovative
8-K
EX-99.1
ONCR
Oncorus, Inc.
4 Aug 21
Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights
7:09am
and innovative approach and, in doing so, potentially create a new pillar of therapy for cancer patients.”
Second Quarter 2021 and Recent Highlights … Synthetic vRNA Immunotherapy Platform involves a highly innovative, novel combination of RNA- and oncolytic virus-based modalities designed to realize
8-K
EX-99.1
83kljb10kh ma6
9 Mar 22
Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
7:46am
8-K
EX-99.1
zcck53v9sgoqkqjmq
12 Nov 21
Entry into a Material Definitive Agreement
7:45am
8-K
EX-99.1
6qacqvmrtp3y1k
15 Jun 21
Regulation FD Disclosure
7:15am
8-K
EX-99.1
pjfxizt48 70
10 Jan 22
Regulation FD Disclosure
8:17am
8-K
EX-99.1
lzibmjyjgzb7b2
9 Nov 21
Regulation FD Disclosure
8:10am
8-K
EX-99.1
5d95ujhh lhz33w
29 Jul 21
Oncorus Expands its Board with Appointment of Barbara Yanni
4:31pm
8-K
EX-99.1
zufqxqlcnu4o0jazfio
7 Dec 20
Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff
9:17am
8-K
jm4dx1x 5g2s4j
23 Jun 22
Oncorus Appoints Douglas Fambrough to Board of Directors
7:21am
8-K
EX-99.1
rppcq8dgk 5pjkvfm8t4
4 Aug 22
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates
9:04am
8-K
EX-99.1
d54bpp1lh f6
2 Nov 22
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
7:11am
8-K
EX-99.1
axla0 2s2wt
4 May 22
Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates
7:15am
8-K
EX-99.1
i1axaijnik9w7wp0e
3 Nov 21
Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates
7:18am
10-K/A
8aho lfwdaesp76bu5
29 Apr 22
Annual report (amended)
4:06pm
DEF 14A
6mszqmc1oz0y6m
28 Apr 21
Definitive proxy
4:06pm